Merit
Laufzeit: 01.01.2017 - 31.12.2025
imported
Kurzfassung
First-in-human Clinical Study with RNA-Immunotherapy Combination of IVAC_W_bre1_ulD and IVAC_M_ulD for individualized Tumor Therapy in triple negative breast cancer patients
Veröffentlichungen
- Heesen, Ludwig; Frenzel, Katrin; Bolte, Stefanie et al.
- Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer (TNBC)
